Ways to increase the effectiveness of hypertension correction during antitumor therapy with the use of VEGF inhibitors

Т. Р. Эйнуллаева
{"title":"Ways to increase the effectiveness of hypertension correction during antitumor therapy with the use of VEGF inhibitors","authors":"Т. Р. Эйнуллаева","doi":"10.17816/rjpbr628823","DOIUrl":null,"url":null,"abstract":"In recent years, cardioncology has rapidly become responsible for comprehensive decision-making appropriate cancer patients receiving cardiotoxic cancer therapy. Currently, the implementation of a multidisciplinary approach in the correction of adverse events using various drug antitumor therapy regimens is becoming increasingly relevant. In particular, given the widespread use of vascular-endothelial growth factor inhibitors, both at the heart of complex schemes and in mono-supportive modes. It is important to timely identify and correct such a clinically significant adverse event as an increase in blood pressure at the time of administration and in the early follow-up period. Adherence to standard drug regimens for hypertension, which usually provide satisfactory blood pressure control between cycles of administration of vascular-endothelial growth factor inhibitors, in a number of patients did not allow the same effective retention of blood pressure in the planned intervals with the administration of bevacizumab. The intensification of drug therapy for hypertension, both at the pre-infusion stage and at the time of an increase in blood pressure, was of a multidirectional nature. \nSearch and summarize information on the availability and development of physiotherapeutic treatment methods for the correction of hypertension during antitumor therapy in cancer patients using vascular-endothelial growth factor inhibitors. 35 literature sources were analyzed. There are no data on the development of physiotherapeutic methods for the treatment of bevacizumab-induced hypertension. Domestic sources ― 25 articles. Foreign sources ― 10 articles. \nAn analysis of the literature concluded that there is a lack of research on the development of physiotherapeutic methods for the treatment of bevacizumab-induced hypertension. In order to reduce the cardiotoxicity of humanized recombined monoclonal antibodies, maintain the dose interval period, improve survival and eliminate the need for dose adjustment of antihypertensive drugs, it is proposed to consider the use of preformed physical factors in the treatment of bevacizumab-induced hypertension.","PeriodicalId":226051,"journal":{"name":"Russian Journal of Physiotherapy, Balneology and Rehabilitation","volume":"9 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Physiotherapy, Balneology and Rehabilitation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17816/rjpbr628823","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In recent years, cardioncology has rapidly become responsible for comprehensive decision-making appropriate cancer patients receiving cardiotoxic cancer therapy. Currently, the implementation of a multidisciplinary approach in the correction of adverse events using various drug antitumor therapy regimens is becoming increasingly relevant. In particular, given the widespread use of vascular-endothelial growth factor inhibitors, both at the heart of complex schemes and in mono-supportive modes. It is important to timely identify and correct such a clinically significant adverse event as an increase in blood pressure at the time of administration and in the early follow-up period. Adherence to standard drug regimens for hypertension, which usually provide satisfactory blood pressure control between cycles of administration of vascular-endothelial growth factor inhibitors, in a number of patients did not allow the same effective retention of blood pressure in the planned intervals with the administration of bevacizumab. The intensification of drug therapy for hypertension, both at the pre-infusion stage and at the time of an increase in blood pressure, was of a multidirectional nature. Search and summarize information on the availability and development of physiotherapeutic treatment methods for the correction of hypertension during antitumor therapy in cancer patients using vascular-endothelial growth factor inhibitors. 35 literature sources were analyzed. There are no data on the development of physiotherapeutic methods for the treatment of bevacizumab-induced hypertension. Domestic sources ― 25 articles. Foreign sources ― 10 articles. An analysis of the literature concluded that there is a lack of research on the development of physiotherapeutic methods for the treatment of bevacizumab-induced hypertension. In order to reduce the cardiotoxicity of humanized recombined monoclonal antibodies, maintain the dose interval period, improve survival and eliminate the need for dose adjustment of antihypertensive drugs, it is proposed to consider the use of preformed physical factors in the treatment of bevacizumab-induced hypertension.
使用血管内皮生长因子抑制剂提高抗肿瘤治疗期间高血压矫正效果的方法
近年来,心脏肿瘤学已迅速成为负责对接受心脏毒性癌症治疗的癌症患者进行综合决策的学科。目前,采用多学科方法纠正各种药物抗肿瘤治疗方案的不良反应正变得越来越重要。特别是鉴于血管内皮生长因子抑制剂的广泛使用,无论是在复杂方案的核心还是在单一支持模式中都是如此。在用药时和早期随访期间及时发现并纠正血压升高这种具有临床意义的不良事件非常重要。一些患者在使用血管内皮生长因子抑制剂的两个周期之间坚持使用标准的高血压药物治疗方案,通常能达到令人满意的血压控制效果,但在使用贝伐珠单抗的计划间隔期内,血压并不能得到同样有效的控制。无论是在输注前阶段还是在血压升高时,加强高血压的药物治疗都具有多向性。搜索并总结有关使用血管内皮生长因子抑制剂的癌症患者在接受抗肿瘤治疗期间纠正高血压的物理治疗方法的可用性和发展情况。分析了 35 篇文献资料。没有关于开发治疗贝伐珠单抗引起的高血压的物理治疗方法的数据。国内文献 - 25 篇。国外资料--10 篇。通过对文献的分析,我们得出结论:目前缺乏关于开发物理治疗方法来治疗贝伐珠单抗诱发的高血压的研究。为了降低人源化重组单克隆抗体的心脏毒性,维持剂量间隔期,提高生存率,无需调整降压药物剂量,建议考虑在贝伐珠单抗诱导的高血压治疗中使用预成物理因子。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信